CYTK Dec 2024 42.000 call
- GuruFocus.com
Insider Selling: Director B Parshall Sells Shares of Cytokinetics Inc (CYTK)
On June 17, 2024, B Parshall, Director at Cytokinetics Inc (NASDAQ:CYTK), executed a sale of 5,000 shares of the company.
- GlobeNewswire
Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 study evaluating the pharmacokinetics, safety and tolerability of aficamten in healthy Japanese and Caucasian participants. “We are conducting this Phase 1 bridging study to characterize the pharmacokinetics of aficamten in healthy Japanese adults and to gather evidence that we believe will be required for potential appr
- GuruFocus.com
Insider Sale at Cytokinetics Inc (CYTK) by EVP of Research & Development
Fady Malik, Executive Vice President of Research & Development at Cytokinetics Inc (NASDAQ:CYTK), sold 7,788 shares of the company on June 11, 2024.
